Full Press Release Details
BridgeBio Pharma And Sentynl Therapeutics Announce Asset Purchase Agreement For BridgeBio Pharma's NULIBRY (fosdenopterin) And Investigational Pediatric Formulation.
BBIO
BridgeBio Pharma And Sentynl Therapeutics Announce Asset Purchase Agreement For BridgeBio Pharma's NULIBRY (fosdenopterin) And Investigational Pediatric Formulation
Key Takeaway: BridgeBio Pharma And Sentynl Therapeutics Announce Asset Purchase Agreement For BridgeBio Pharma's NULIBRY (fosdenopterin) And Investigational Pediatric Formulation